abstract |
The present invention relates to the use of K252a, a physiologically active substance produced by microorganisms, and their salts and synthetic and / or chemically modified derivatives for the prevention or treatment of pathologies associated with HMGB1. more particularly, the present invention relates to the use of K-252a. for the prevention or treatment of restenosis. |